Lai Wang
Chief Tech/Sci/R&D Officer chez BEIGENE, LTD.
Fortune : 20 M $ au 31/03/2024
Profil
M. Lai Wang est responsable mondial de la recherche et du développement chez BeiGene Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BEIGENE LTD
0,13% | 26/06/2023 | 1 658 215 ( 0,13% ) | 20 M $ | 31/03/2024 |
Postes actifs de Lai Wang
| Sociétés | Poste | Début |
|---|---|---|
| BEIGENE, LTD. | Chief Tech/Sci/R&D Officer | 01/04/2021 |
Anciens postes connus de Lai Wang
| Sociétés | Poste | Fin |
|---|---|---|
Joyant Pharmaceuticals, Inc.
 Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Corporate Officer/Principal | - |
Formation de Lai Wang
| Fudan University | Undergraduate Degree |
| University of Texas Health Science Center at Houston | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BEIGENE, LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
